Pharmacy Daily | Cycloblastin cut

PFIZER Australia has advised healthcare professionals that its Cycloblastin (cyclophaphamaide) 50mg x 50 tablets are being discontinued effective from 01 Oct. “The product is being discontinued because the manufacturer has advised that they are not able to produce the product any longer...there is no safety, quality nor efficacy concern in relation to this product,” Pfizer said in a letter earlier this month. Cycloblastin is indicated for the treatment of a range of neoplastic conditions, autoimmune diseases and immunotherapies and for the treatment of transplant rejection. It’s the only oral formulation on the market, with clinicians advised to review their current patients and develop a transition plan to avoid reliance on Cycloblastin beyond the beginning of October this year. Alternative therapies include intravenous cyclophosphamide - for further details call 1800 629 921.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 29 Apr 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Apr 13